Aggressive tumor progression during immunosuppressive therapy with abatacept
Copyright © 2021 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION: Co-stimulatory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibits T-cell activation. Clinically, CTLA-4 has been targeted in opposite ways: its blockade enhances antitumor immunity in the field of oncology, whereas CTLA-4 agonists such as abatacept are used for the treatment of immuno-inflammatory diseases as rheumatoid arthritis (RA).
OBSERVATION: We herein report the case of a 69-year-old man with a history of severe RA successfully treated with abatacept, who showed unusually rapid progression of undifferentiated multi-metastatic carcinoma.
DISCUSSION: Although no significant increase in malignancy has been reported in abatacept-treated patients, several case reports have documented the possible association with the acceleration of the progression of malignancy. Here, abatacept may have altered immune surveillance and hence allowed tumor growth.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
La Revue de medecine interne - 42(2021), 7 vom: 07. Juli, Seite 505-508 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Une progression tumorale fulgurante sous abatacept |
|---|
| Beteiligte Personen: |
Lapoirie, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7D0YB67S97 |
|---|
| Anmerkungen: |
Date Completed 24.11.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.revmed.2021.03.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323940196 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323940196 | ||
| 003 | DE-627 | ||
| 005 | 20231225185244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.revmed.2021.03.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323940196 | ||
| 035 | |a (NLM)33838949 | ||
| 035 | |a (PII)S0248-8663(21)00075-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lapoirie, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aggressive tumor progression during immunosuppressive therapy with abatacept |
| 246 | 3 | 3 | |a Une progression tumorale fulgurante sous abatacept |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: Co-stimulatory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibits T-cell activation. Clinically, CTLA-4 has been targeted in opposite ways: its blockade enhances antitumor immunity in the field of oncology, whereas CTLA-4 agonists such as abatacept are used for the treatment of immuno-inflammatory diseases as rheumatoid arthritis (RA) | ||
| 520 | |a OBSERVATION: We herein report the case of a 69-year-old man with a history of severe RA successfully treated with abatacept, who showed unusually rapid progression of undifferentiated multi-metastatic carcinoma | ||
| 520 | |a DISCUSSION: Although no significant increase in malignancy has been reported in abatacept-treated patients, several case reports have documented the possible association with the acceleration of the progression of malignancy. Here, abatacept may have altered immune surveillance and hence allowed tumor growth | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abatacept | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Immunosurveillance | |
| 650 | 4 | |a Polyarthrite rhumatoïde | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Abatacept |2 NLM | |
| 650 | 7 | |a 7D0YB67S97 |2 NLM | |
| 700 | 1 | |a Lefort, F |e verfasserin |4 aut | |
| 700 | 1 | |a Mériglier, E |e verfasserin |4 aut | |
| 700 | 1 | |a Rivoisy, C |e verfasserin |4 aut | |
| 700 | 1 | |a Contis, A |e verfasserin |4 aut | |
| 700 | 1 | |a Vandenhende, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnet, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue de medecine interne |d 1983 |g 42(2021), 7 vom: 07. Juli, Seite 505-508 |w (DE-627)NLM012660108 |x 1768-3122 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:7 |g day:07 |g month:07 |g pages:505-508 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.revmed.2021.03.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 7 |b 07 |c 07 |h 505-508 | ||